This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Uncover various ways to earn money online without skills, making it accessible for everyone to start earning.
21,829 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Discover how Claros Mortgage Trust CMTG generates income, navigates rate risk, and positions its portfolio for the ne...
Looking for a higher yield consistent dividend or steady dividend growth? This in-depth guide compares VIG and FDVV, ...
Rocket Lab is expanding by purchasing a competing space systems group for up to $60 million. This article breaks down...
Curve rolls out Llamalend v2 on Optimism, expanding collateral and borrowing options. The upgrade comes with a 250,00...
July 2026 offers a compelling setup for patient investors. Here’s my top-ranked stock for July, why it stands out, an...
A new private space station race is heating up, and Vast is stepping in with a bold plan. This could shift how invest...
Geopolitics can push oil to $100 a barrel, but certain pipeline stocks thrive on throughput rather than price. Learn ...
When a stock stalls, a disciplined fund can still see value in the long run. This article explains why this fund made...
A new Xbox CEO rises amid a changing gaming landscape. Her career path—from janitorial work to coupon sales to the C-...
A weekend wave of strikes targeted Russian oil terminals, including in St. Petersburg, intensifying a fuel squeeze an...
Rolex opens a tuition-free watchmaking training center in Dallas to tackle a shrinking U.S. talent pool, drawing hund...